» Articles » PMID: 33763413

Cord Lining Mesenchymal Stem Cells Have a Modest Positive Effect on Angiogenesis in Hindlimb Ischemia

Overview
Specialty Cell Biology
Date 2021 Mar 25
PMID 33763413
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the use of human Cord Lining Mesenchymal Stem Cells (CL-MSCs) (US Patent number 9,737,568), in a rabbit hindlimb ischemia model, and evaluated their potential in stimulating neovascularization. Allogenic human CL- MSCs could potentially be used to treat patients with lower limb ischemia and non-healing wounds. Twenty rabbits were divided into two separate groups. We created a hindlimb ischemia model surgically. At 21 and 49 days post-operatively, animals in the treatment group were injected with CL-MSCs (500,000 cells per 0.2 ml on each site) at 10 different sites (Quadriceps- 4 sites, Hamstrings- 4 sites and Calf--2 sites) in the hindlimb muscles. The control group received only saline injection to the corresponding sites at the same time point as the treatment group. We then evaluated the effects of treatment on neovascularization by angiography, laser doppler perfusion imaging, as well as by histology. We evaluated the tissue samples for any signs of local immune reaction to the cell implantation. We also observed the rabbit clinically for any adverse effects after treatment. We found a higher number of CD31 positive cells in the treatment group, with a greater number of capillaries found in the treated muscles. The Rectus Femoris demonstrated a median vessel count/muscle fiber of 0.121 for the treatment group, compared to 0.076 in the control group (median difference 0.04; 95% CI 0.001-0.11; = 0.041). The Gastrocnemius demonstrated a median vessel count/muscle fiber of 0.175 for the treatment group, compared to 0.089 in the control group (median difference 0.087; 95% CI -0.006 to 0.234; = 0.07). Blood perfusion quantification through Laser Doppler Perfusion Imaging (LDPI) also demonstrated a non-statistically significant increase in perfusion in favor of the treatment group. CL-MSCs demonstrated no toxicity associated morbidity and minimal local immune reaction to implantation. CL-MSCs have a positive effect on angiogenesis in a rabbit hindlimb ischemia model. This preliminary data is encouraging and paves the way for future large animal studies or for clinical trials.

Citing Articles

Transmembrane stem factor nanodiscs enhanced revascularization in a hind limb ischemia model in diabetic, hyperlipidemic rabbits.

Takematsu E, Massidda M, Howe G, Goldman J, Felli P, Mei L Sci Rep. 2024; 14(1):2352.

PMID: 38287067 PMC: 10825164. DOI: 10.1038/s41598-024-52888-6.

References
1.
Shishehbor M, White C, Gray B, Menard M, Lookstein R, Rosenfield K . Critical Limb Ischemia: An Expert Statement. J Am Coll Cardiol. 2016; 68(18):2002-2015. DOI: 10.1016/j.jacc.2016.04.071. View

2.
Martinez E, Vu D, Wang J, Lilyanna S, Ling L, Gan S . Grafts enriched with subamnion-cord-lining mesenchymal stem cell angiogenic spheroids induce post-ischemic myocardial revascularization and preserve cardiac function in failing rat hearts. Stem Cells Dev. 2013; 22(23):3087-99. PMC: 3856952. DOI: 10.1089/scd.2013.0119. View

3.
Jelani Q, Harchandani B, Cable R, Guo Y, Zhong H, Hilbert T . Effects of serial phlebotomy on vascular endothelial function: Results of a prospective double-blind randomized study. Cardiovasc Ther. 2018; 36(6):e12470. PMC: 6351195. DOI: 10.1111/1755-5922.12470. View

4.
Liew A, OBrien T . Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther. 2012; 3(4):28. PMC: 3580466. DOI: 10.1186/scrt119. View

5.
Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J . Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem. 2007; 20(6):867-76. DOI: 10.1159/000110447. View